AbCellera Biologics Inc. Common Shares (ABCL)
ABCL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/0001703057-26-000012-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ABCL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | 2020 |
| SEC CIK | 0001703057 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | BC |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $75.1M |
| Net income | -$146.4M |
| Operating income | -$217.1M |
| Net margin | -194.9% |
| Operating margin | -289.0% |
| Revenue growth | +160.6% |
| Cash | $128.5M |
| Total assets | $1.4B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 48.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $163.8M cash; operating cash flow -$3.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 326,617,896 (2026-11-04); 299,335,048 a year earlier; 290,170,241 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-08-13 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Vancouver, Canada; changed auditors 1 time in 24 months | 8-K 4.01 2025-11-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $2.7M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $10.6M | -$40.8M | $26.9M | $163.8M | No debt tags | $67.9M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $4.0M | -$55.4M | $25.9M | $120.1M | No debt tags | $66.2M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $8.3M | -$43.2M | -$33.5M | $77.1M | No debt tags | $79.2M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $44.9M | -$8.9M | -$34.7M | $128.5M | No debt tags | $75.1M | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $9.0M | -$57.1M | -$52.6M | $83.2M | No debt tags | $35.3M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $17.1M | -$34.7M | -$32.4M | $92.4M | No debt tags | $32.9M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $4.2M | -$45.6M | -$11.6M | $159.3M | No debt tags | $23.1M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $5.0M | -$34.2M | -$8.0M | $156.3M | No debt tags | $28.8M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-13 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 329 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.3% |
| 1 month | -8.9% |
| 3 months | +4.7% |
| Year to date | +236.0% |
| 1 year | +217.4% |
| From 52-week high | -22.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OGN | Organon & Co. Common Stock | $13.90 | 0.00% | $3.7B |
| AMLX | Amylyx Pharmaceuticals Inc. | $27.80 | -8.22% | $3.6B |
| PBLS | Parabilis Medicines Inc. | $28.45 | +0.07% | $3.5B |
| ELVN | Enliven Therapeutics Inc. | $47.62 | -2.42% | $3.5B |
| IRON | Disc Medicine Inc. | $76.59 | -4.26% | $3.5B |
| ARQT | Arcutis Biotherapeutics Inc. | $27.15 | -3.93% | $3.4B |
| XENE | Xenon Pharmaceuticals Inc. Common Shares | $39.26 | -3.01% | $3.9B |
| VKTX | Viking Therapeutics Inc. | $26.80 | -8.28% | $3.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier